Health (Drugs and Poisons) Regulation 1996

Drug Therapy Protocol – Pharmacist UTI Trial

Healthcare Approvals and Regulation Unit
Chief Medical Officer and Healthcare Regulation Branch
Queensland Health
Email: HARU@health.qld.gov.au
Health (Drugs and Poisons) Regulation 1996
Drug Therapy Protocol – Pharmacist UTI Trial

I, Dr John Wakefield, certify this document under the Health (Drugs and Poisons) Regulation 1996 (Qld) as the Drug Therapy Protocol – Pharmacist UTI Trial.

Authority
For the purpose of participating in the Urinary Tract Infection Pharmacy Pilot – Queensland (UTIPP-Q), a pharmacist may sell and supply a restricted drug listed in Appendix 1, Table 1 of this Drug Therapy Protocol without the requirement for a prescription or a purchase order —

a) the drug stated in column 1; and
b) subject to the restrictions for the drug stated opposite in column 2 (if any); and
c) in accordance with the treatment protocol established under the UTIPP-Q.

UTIPP-Q
The UTIPP-Q has been implemented as part of the Government Response to the Inquiry into the establishment of a pharmacy council and transfer of pharmacy ownership in Queensland. The Department of Health has engaged the Queensland University of Technology to manage the implementation and evaluation of the trial.

The endorsed model of care for the trial enables a community pharmacist to provide empirical treatment, in accordance with the Pharmaceutical Society of Australia Guidance for provision of antibiotics for acute uncomplicated cystitis in women. and records data for the research evaluation using the GuildCare NG UTIPP-Q recording module developed for the trial.

Conditions
1. Before undertaking any action under authority of this Drug Therapy Protocol, the pharmacist must have:
   (i) Registered, and been accepted into, the UTIPP-Q with the Queensland University of Technology (QUT); and
   (ii) Completed the requisite training to participate in the UTIPP-Q. and
   (iii) Access to the GuildCare NG UTIPP-Q recording module, to record data for the research evaluation
2. The pharmacist must maintain eligibility to participate in the UTIPP-Q, including any training and registration requirements.
3. The pharmacist may sell and supply a restricted drug specified in this Drug Therapy Protocol to a person without prescription only for the treatment of acute uncomplicated cystitis in a non-pregnant woman and where the pharmacist reasonably believes the sale and supply of the restricted drug is essential for the woman’s wellbeing.
4. Before selling and supplying a restricted drug under this Drug Therapy Protocol, the pharmacist must advise the client of the contra-indications and known side effects of the drug. If the supply of one of the restricted drugs specified in this Drug Therapy
Protocol is not an appropriate treatment option (for example, due to contraindications), then the pharmacist has the option to supply one of the other two drugs. However, the pharmacist must refer the client to a medical practitioner if the referral criteria is met or all three drugs are inappropriate.

5. The pharmacist must not sell and supply a restricted drug specified in this Drug Therapy Protocol in quantities that are more than a single manufacturer’s pack of the restricted drug.

6. The pharmacist must only sell and supply a restricted drug under this Drug Therapy Protocol in a container that has on it a securely attached label as per Section 198 of the Health (Drugs and Poisons) Regulation 1996.

7. The pharmacist must, when selling and supplying a restricted drug under this Drug Therapy Protocol, keep a record of the following information—

(i) the name and address of the person to whom the restricted drug was sold and supplied;

(ii) the date the restricted drug is sold and supplied;

(iii) the description and quantity or volume of the restricted drug sold and supplied; and

(iv) the directions given for the use of the restricted drug.

**Important information**

All other relevant provisions of the Health (Drugs and Poisons) Regulation 1996 must be complied with.

A pharmacist engaging in activities under authority of this Drug Therapy Protocol is not relieved of their general legal responsibility or accountability for their actions.

Certified at Brisbane on this 5th day of June 2020

Dr John Wakefield  
**Director-General**  
Queensland Health
### Appendix 1

#### Table 1

<table>
<thead>
<tr>
<th>COLUMN 1 RESTRICTED DRUG</th>
<th>COLUMN 2 RESTRICTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimethoprim</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Sale and supply limited to circumstances where Trimethoprim is not appropriate for the patient</td>
</tr>
<tr>
<td>Cefalexin</td>
<td>Sale and supply limited to circumstances where Trimethoprim and Nitrofurantoin are not appropriate for the patient</td>
</tr>
</tbody>
</table>